HEALTHCARE

29 Sep 2014

Egypt still Ebola-free, says health ministry

An Egyptian citizen quarantined after arriving from Sierra Leona tests negative for the Ebola virus.

The Ministry of Health announced on Sunday that Egypt was still Ebola-free and that an Egyptian citizen quarantined after returning from Sierra Leone last week did not suffer from any Ebola virus"...

Continue Reading

28 Sep 2014

AZD9291 Shows Durable Clinical Response in Patients with Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer at the ESMO 2014 Congress

IMPRESS Study Results also Presented at the ESMO 2014 Congress Provide Increased Understanding of Treatment Options for Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer who have Developed Acquired Resistance to First Line IRESSA


...

Continue Reading

27 Sep 2014

Head-to-head Phase III Trial Demonstrates Superior Progression-Free Survival for Afatinib Compared to Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung

  • LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib* versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing the risk of disease progression by 18%
  • Overall rate of severe adverse events (≥ grade 3) was comparable between both therapies
  • Limited...

    Continue Reading

27 Sep 2014

Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis

In phase III studies, OTEZLA resulted in significant and clinically meaningful improvements in plaque psoriasis


OTEZLA demonstrated a consistent safety and tolerability profile across clinical trials

Celgene Corporation (NASDAQ: CELG) today"......

Continue Reading

26 Sep 2014

cloudBuy Delivers Peak Performance eCommerce Initiative Across GCC And Asia

Ronald Duncan, Chairman and CIO at cloudBuy plc, the world’s leading transactional cloud platform, has delivered a presentation at the GCC Municipalities and Smart Cities Conference in Dubai on how cloudBuy enables smart cities through improved purchasing, government to citizen engagement and economic development.


......

Continue Reading

26 Sep 2014

Nintedanib* Receives Positive CHMP Opinion for Second-Line Treatment of Patients with Adenocarcinoma of the Lung

• Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have provided over one year overall survival for patients with advanced adenocarcinoma, after first-line chemotherapy

• Adenocarcinoma"...

Continue Reading

24 Sep 2014

Egypt's heath minister to agree with Hep C treatment company on second shipment

With a total of around 12 million Egyptians currently infected, each shipment will be used to treat only 70,000 patients with a total of 140,000 patients treated by June 2015.

Egypt's health minister met on Tuesday with the chief executive officer of the company producing the Hepatitis C drug"...

Continue Reading

22 Sep 2014

Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry

(BUSINESS WIRE)

  • Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)
  • Acquisition expands Merck Millipore’s global reach, increasing the company’s presence in North America and adding exposure to"...

    Continue Reading

21 Sep 2014

ADP: Comprehensive Medical Conference Combines Experience to Improve Women’s Health

The Abu Dhabi Police Medical Services Department confirmed that the Comprehensive Medical Conference, which will be held in the next month, combines the expertise of local and international doctors. The Conference will contribute to the improvement of medical care for women and open new"...

Continue Reading

19 Sep 2014

Boehringer Ingelheim and CureVac Announce Collaboration to Develop Next Generation Lung Cancer Immunotherapy

  • Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202
  • CV9202 is based on CureVac’s mRNA technology (RNActive®)
  • Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings,...

    Continue Reading
Found articles: 19 - Pages  1 2 
Contact US | Powered by CNPHUB.com - All Rights Reserved